Loading provider…
Loading provider…
Infectious Disease Physician in New York, NY
NPI: 1255421426Primary Practice Location
NEW YORK-PRESBYTERIAN HOSPITAL
5141 Broadway, New York, NY
Primary Employer
Weill Medical College of Cornell
med.cornell.edu
HQ Phone
Get MD Kristen's Phone Numberphone_androidMobile
Get MD Kristen's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNY State Medical License
NY State Medical License
2001 - 2027

American Board of Internal Medicine
Infectious Disease
Vagelos College of Physicians and Surgeons
vagelos.columbia.edu
Medical School
Until 1999
New York Presbyterian Hospital (Cornell Campus)
Fellowship • Infectious Disease
2002 - 2005
Residency • Internal Medicine
1999 - 2002
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 36 | 92 |
| 2 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 28 | 28 |
Authors: Asa Radix, Bisher Akil, Shirish Huprikar, Andrew Talal, Daniel Fierer
Journal: PLoS One
Publication Date: 2020-07-15
Authors: Ronald Nahass, Raymond Chung, Ravi Jhaveri, Maureen Jonas, Timothy Morgan, Marion Peters, Norah Terrault, Debika Bhattacharya
Journal: Clin Infect Dis
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Dynavax Technologies Corporation
Intervention / Treatment: BIOLOGICAL: HEPLISAV-B, BIOLOGICAL: ENGERIX-B
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: Gilead Sciences
Intervention / Treatment: OTHER: Rapid Treatment strategy, OTHER: Usual Care (facilitated referral)
Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Intervention / Treatment: DRUG: ribavirin, DRUG: pioglitazone, DRUG: peginterferon